XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Other Financial Information | 9 Months Ended
--- | ---
Oct. 02, 2022
Other Financial Information [Abstract] |
Other Financial Information | Other Financial Information A. Inventories
The following summarizes the components of Inventories:
(MILLIONS) |  | October 2, 2022 |  | December 31, 2021
Finished goods |  | $ | 3,159 |  |  | $ | 3,641 |
Work-in-process |  | 4,540 |  |  | 4,424 |
Raw materials and supplies |  | 1,813 |  |  | 994 |
Inventories(a) |  | $ | 9,513 |  |  | $ | 9,059 |
Noncurrent inventories not included above(b) |  | $ | 3,327 |  |  | $ | 939 |
(a)The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand. (b)Included in Other noncurrent assets. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts. B. Other Current Liabilities Other current liabilities includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $4.5 billion as of October 2, 2022 and $9.7 billion as of December 31, 2021.

X
- Definition Other Financial Information + References No definition available. + Details
Name: | pfe_OtherFinancialInformationAbstract
Namespace Prefix: | pfe_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration